Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) CFO Maximo F. Nougues sold 10,499 shares of Puma Biotechnology stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $4.18, for a total transaction of $43,885.82. Following the completion of the transaction, the chief financial officer now directly owns 100,427 shares of the company's stock, valued at approximately $419,784.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Puma Biotechnology Stock Up 4.8 %

Shares of NASDAQ PBYI opened at $4.82 on Friday. The company's 50-day simple moving average is $4.04 and its 200-day simple moving average is $3.22. Puma Biotechnology, Inc. has a 52-week low of $1.60 and a 52-week high of $5.16. The firm has a market cap of $219.98 million, a price-to-earnings ratio of 21.91, a price-to-earnings-growth ratio of 2.12 and a beta of 0.92. The company has a quick ratio of 1.95, a current ratio of 2.04 and a debt-to-equity ratio of 4.42.

Puma Biotechnology (NASDAQ:PBYI – Get Rating) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.10. The business had revenue of $57.10 million for the quarter, compared to analyst estimates of $51.40 million. Puma Biotechnology had a net margin of 4.50% and a return on equity of 84.14%. Equities analysts predict that Puma Biotechnology, Inc. will post 0.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Puma Biotechnology

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Puma Biotechnology in a research report on Wednesday, October 12th. They issued a "buy" rating on the stock.

About Puma Biotechnology

(Get Rating)

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.

Featured Stories

• Get a free copy of the StockNews.com research report on Puma Biotechnology (PBYI)
• MarketBeat: Week in Review 01/02-01/06
• Why is the CrowdStrike Stock Price Struggling?
• Four Undervalued Healthcare Stocks for 2023
• WWE Stock: Vince McMahon Wants Back In The Show
• NVIDIA Is Bottoming But Don't Buy It Just Yet

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.